Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke: Preliminary observations

Stroke

Volumn 34, Issue 8, 2003, Pages 1932-1935

  Seitz, Rüdiger J ^a,c   Hamzavi, Magnolia ^a   Junghans, Ulrich ^a   Ringleb, Peter A ^b   Schranz, Corinna ^b   Siebler, Mario ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Platelet glycoprotein GPIIb IIIa complex; Platelets; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE; TIROFIBAN;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBRAL ARTERY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFECT; FEMALE; HUMAN; MALE; MORTALITY; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FIBRINOLYTIC AGENTS; HUMANS; PILOT PROJECTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; TYROSINE;

EID: 0042122432     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000080535.61188.A6     Document Type: Article

References (38)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Fiorelli M, Bastianello S, von Kummer R, del Zoppo GJ, Larrue V, Lesaffre E, Ringleb PA, Lorenzano S, Manelfe C, Bozzao L. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke. 1999;30: 2280-2284.
3. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998; 352:1245-1251.
4. Alexandrov AV, Black SE, Ehrlich LE, Caldwell CB, Norris JW. Predictors of hemorrhagic transformation occurring spontaneously and on anticoagulants in patients with acute ischemic stroke. Stroke. 1997;28: 1198-202.
5. Furlan AJ, Kanoti G. When is thrombolysis justified in patients with acute ischemic stroke? A bioethical perspective. Stroke. 1997;28:214-218.
6. Kaste M, Thomassen L, Grond M, Hacke W, Holtas S, Lindley RI, Roine R, Gunnar Wahlgren N, Wardlaw JM. Thrombolysis for acute ischemic stroke: a consensus statement of the 3rd Karolinska Stroke Update, October 30-31, 2000. Stroke. 2001;32:2717-2718.
7. Junghans U, Seitz RJ, Wittsack H-J, Aulich A, Siebler M. Treatment of acute basilar artery thrombosis with a combination of systemic alteplase and tirofiban, a nonpeptide platelet glycoprotein IIb/IIIa inhibitor: report of four cases. Radiology. 2001;221:795-801.
8. Calais P, Bock K, Herrlinger JD, Schommer B, Schroder J. Lysis of an extensive thrombus in the internal carotid artery using a glycoprotein IIb/IIIa receptor antagonist. Dtsch Med Wochenschr. 2001;126:680-683.
9. Junghans U, Seitz RJ, Ritzl A, Wittsack HJ, Fink GR, Freund HJ, Siebler M. Ischemic brain tissue salvaged from infarction by the GP IIb/IIIa platelet antagonist tirofiban. Neurology. 2002;58:474-476.
10. Liebeskind DS, Pollard JR, Schwartz ED, Cucchiara BL, McGarvey ML, Hurst RW. Vertebrobasilar thrombolysis with intravenous tirofiban: case report. J Thromb Thrombolysis. 2002;13:81-84.
11. Eckert B, Koch C, Thomalla G, Roether J, Zeumer H. Acute basilar artery occlusion treated with combined intravenous abciximab and intra-arterial tissue plasminogen activator: report of 3 cases. Stroke. 2002;33: 1424-1427.
12. Harker LA. Therapeutic inhibition of platelet function in stroke. Cerebrovasc Dis. 1998;8(suppl 5):8-18.
13. Kulkarni S, Dopheide SM, Yap CL, Ravanat C, Freund M, Mangin P, Heel KA, Street A, Harper IS, Lanza F, Jackson SP. A revised model of platelet aggregation. J Clin Invest. 2000;105:783-791.
14. Peerlinck K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, Panebianco D, Deckmyn H, Vermylen J, Arnout J. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation. 1993;88:1512-1517.
15. Choudhri TF, Hoh BL, Zerwes HG, et al. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Invest. 1998; 102:1301-1310.
16. Abumiya T, Fitridge R, Mazur C, et al. Integrin α(IIb)β(3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke. 2000;31:1402-1409.
17. Busch E, Kruger K, Allegrini PR, Kerskens CM, Gyngell ML, Hoehn-Berlage M, Hossmann KA. Reperfusion after thrombolytic therapy of embolic stroke in the rat: magnetic resonance and biochemical imaging. J Cereb Blood Flow Metab. 1998;18:407-418.
18. Winkley JM, Adams HP. Potential role of abciximab in ischemic cerebrovascular disease. Am J Cardiol. 2000;85:47C-51C.
19. Radke PW, Janssens U, Schwarz ER, vom Dahl J. Therapeutic dissolution of an intracoronary thrombus by prolonged intravenous platelet glycoprotein IIb/IIIa antagonism. J Invasive Cardiol. 1999;11:679-681.
20. Cecena FA, Hoelzinger DH, Miller JA, Abu-Shakra S. The platelet IIb/IIIa inhibitor abciximab as adjunctive therapy in carotid stenting of potential thrombotic lesions. J Interven Cardiol. 1999;12:355-361.
21. The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke. 2000;31:601-609.
22. Junghans U, Seitz RJ, Aulich A, Freund H-J, Siebler M. Bleeding risk of tirofiban, a nonpeptide GPII/IIIa platelet receptor antagonist in progressive stroke: an open pilot study. Cerebrovasc Dis. 2001;12:1-5.
23. Shuaib A, Yang Y, Nakada MT, Li Q, Yang T. Glycoprotein IIb/IIIa antagonist, murine 7E3 F(ab′) 2, and tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy. J Cereb Blood Flow Metab. 2002;22:215-222.
24. Lincoff AM, Topol EJ. Illusion of reperfusion: does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation. 1993;88:1361-1374.
25. de Lemos JA, Gibson CM, Antman EM, Murphy SA, Morrow DA, Schuhwerk KC, Schweiger M, Coussement P, Van de Werf F, Braunwald E. Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial. Am Heart J. 2001;141:592-598.
26. Sarullo FM, Pasquale PD, D'Alfonso G, Amerigo L, Cannizzaro S, Castello A. Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings. Ital Heart J. 2001;2:605-611.
27. Lee DH, Jo KD, Kim HG, Choi SJ, Jung SM, Ryu DS, Park MS. Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study. J Vasc Interv Radiol. 2002;13:769-774.
28. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20: 864-870.
29. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
30. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction [published correction appears in N Engl J Med. 1998;339:415]. N Engl J Med. 1998;338:1488-1497.
31. Antman EM, Giugliano RP, Gibson M, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AAJ, Menown I, Rupprecht H-J, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation. 1999;99:2720-2732.
32. Felberg RA, Okon NJ, El-Mitwalli A, Burgin WS, Grotta JC, Alexandrov AV. Early dramatic recovery during intravenous tissue plasminogen activator infusion: clinical pattern and outcome in acute middle cerebral artery stroke. Stroke. 2002;33:1301-1307.
33. Eckert B, Kucinski T, Pfeiffer G, Groden C, Zeumer H. Endovascular therapy of acute vertebrobasilar occlusion: early treatment onset as the most important factor. Cerebrovasc Dis. 2002;14:42-50.
34. Molina CA, Alvarez-Sabin J, Montaner J, Abilleira S, Arenillas JF. Coscojuela P, Romero F, Codina A. Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke. 2002;33:1551-1556.
35. Moonis M, Fisher M. Considering the role of heparin and low-molecular-weight heparins in acute ischemic stroke. Stroke. 2002;33:1927-1933.
36. Brott TG, Haley EC, Levy DE, Barsan W, Broderick J, Shepp GL, Spilker J, Kongable GL, Massey S, Reed R, et al. Urgent therapy for stroke, part 1: pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632-640.
37. Haley EC, Levy DE, Brott TG, Sheppard GL, Wong MC, Kong GL, Torner Jc, Marler JR. Urgent therapy for stroke, part 2: pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke. 1992;23:641-645.
38. Selim M, Fink JN, Kumar S, Caplan LR, Horkan C, Chen Y, Linfante I, Schlaug G. Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke. 2002;33:2047-2052.